<DOC>
	<DOCNO>NCT00337376</DOCNO>
	<brief_summary>Rapamycin drug approve Food Drug Administration ( government ) use patient receive kidney transplant prevent patient 's body rejecting transplant kidney . It show antitumor effect laboratory , approve time treatment cancer . Abraxane new form chemotherapy approve Food Drug Administration treatment metastatic breast cancer , promise drug evaluate clinical trial treatment cancer . This phase I study design find different dos Rapamycin , combine Abraxane , safe well tolerate .</brief_summary>
	<brief_title>A Study mTOR Inhibitor Rapamycin ( Rapamune , Sirolimus ) Combination With Abraxane Advanced Solid Cancers</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients must histologicallyconfirmed advanced solid tumor . For patient metastatic breast cancer , restriction prior therapy . For patient advanced solid tumor , must refractory standard therapy curative standard therapy exist , consider . Metastatic disease , present , progress require palliative treatment within 4 week enrollment base clinical assessment investigator . Development new lesion increase preexist lesion bone scintigraphy , CT , MRI physical examination . Patients sole criterion progression increase biochemical marker , e.g. , carcinoembryonic antigen ( CEA ) , increase symptom , eligible . No radiotherapy , treatment cytotoxic agent , treatment biologic agent within 4 week prior begin treatment study ( 6 week mitomycin nitrosoureas ) . At least 2 week must elapse prior surgery hormonal therapy . Patients must fully recover acute toxicity prior treatment cytotoxic drug , radiotherapy anticancer modality ( return baseline status note recent treatment ) . Patients persist , stable chronic toxicity prior treatment ≤ grade 1 eligible . Age ≥18 year . ECOG performance status ≤2 ( Karnofsky ≥60 % , see Appendix A ) . Life expectancy great 3 month . Patients must normal organ marrow function define : Hemoglobin ≥ 9 g/dL leukocyte ≥3,000/mcL absolute neutrophil count ≥1,500/mcL platelets ≥100,000/mcL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) 2.5 X institutional upper limit normal creatinine within 1.5 x ULN OR creatinine clearance ≥50 mL/min/1.73 m² patient creatinine level ≥1.5 ULN . Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation must negative serum urine pregnancy test within 1 week prior begin treatment trial . Pregnant nursing patient exclude effect combination Abraxane Rapamycin fetus nursing child unknown . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Sexually active men must also use appropriate contraception method father child receive therapy study . Ability understand willingness sign write informed consent document . Fasting serum cholesterol &lt; 350 mg/d L triglycerides &lt; 400 mg/ L. Biopsy require patient physician may opt part trial sufficient justification provide . Justification must provide PI write indicate excessive physical risk psychological trauma biopsy take Patients must 4 week chemotherapy radiotherapy recover adverse event Patients may receive investigational agent . Patients know active brain metastasis . Patients must complete definitive treatment brain metastasis , least 4 week prior first dose study , steroid least 2 week , stable regress CNS lesion MRI CT scan , evidence new lesion . History allergic reaction attribute compound similar chemical biologic composition agent use study . Peripheral neuropathy ≥ Grade 2 Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant woman exclude study investigational agent may potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother agent , breastfeed discontinue mother treat . HIVpositive patient ineligible patient increase risk lethal infection treat marrowsuppressive therapy potential pharmacokinetic interaction antiretroviral therapy investigational agent . All herbal alternative medication discontinue study , include limited : Hydrastis canadensis ( goldenseal ) , Uncaria tomentosa ( cat 's claw ) Echinacea angustifolia Use medication within 1 week , prior first dose treatment : cyclosporine , diltiazem , ketoconazole , rifampin , fluconazole , delavirdine , nicardipine , pioglitazone sulfonamide , erythromycin , clarithromycin , itraconazole , metoclopramide , nevirapine , Phenobarbital , phenytoin , indinavir fosamprenavir , ritonavir , efavirenz , nefazadone , St. John 's wort . Consumption grapefruit juice prohibit study . Requirement treatment warfarin ( Coumadin ) , immunosuppressive agent chronic steroid Prior therapy rapamycin , rapamycin analog experimental agent target mTOR Prior Abraxane therapy Active infection treatment systemic infection within 14 day enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>